This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
According to the company, the primary safety endpoint was achieved at all timepoints with all doses well-tolerated and no treatment-related our serious adverse events.
According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.
According to Apellis Pharmaceuticals, the submission will be a Major Amendment to the NDA, extending the review period by three months with an expected PDUFA target action date in February.
Medicare’s 2023 fee schedule includes cuts in reimbursement, which some groups say could lead to reduced access to care to patients who need it most.
Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.
The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.
Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.
Replay is launching Eudora, an HSV gene therapy company that will target genetic retinal diseases.
Prevent Blindness offers videos, fact sheets, social media graphics and PowerPoint presentations to help ophthalmologists educate the public on the potential effects diabetes may have on vision.
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.
Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.
The 10-year retrospective ALOFT study details the importance of digital remote monitoring for patients diagnosed with age-related macular degeneration.
Complimentary registration is open for this unique meeting designed to prepare young ophthalmologists for success in early practice.
The COVID-19 pandemic has led to greater comfort with robotic telepresence in eye screenings.
The company noted that the pediatric exclusivity determination is based on data from two Phase 3 trials – BUTTERFLEYE and FIREFLEYE.
An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.
Baseline age, best-corrected visual acuity, and central subfield thickness play role in predicting the efficacy of both drugs.
Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.
The therapy may offer novel treatment strategy with unique mechanism, modality for patients diagnosed with dry age-related macular degeneration.
A team of National Institutes of Health scientists have shed light on how genetic architecture determines gene expression, tissue-specific function, and disease phenotype in blinding diseases.
Murtaza Adam, MD, a vitreoretinal specialist with Colorado Retina Associates, shares a few principles he has found helpful when engaging with industry or trying to execute on your own innovation.
This post-hoc analysis was performed to evaluate immunogenicity over the long term.
.png "Optometry Times"){kind=logo}
